Ginkgo Bioworks Holdings, Inc. (DNA) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
DNA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DNA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 81.5% | -185.3% | -183.8% |
| 2024 | 83.0% | -246.5% | -240.9% |
| 2023 | 78.5% | -343.8% | -355.1% |
| 2022 | 57.3% | -462.4% | -440.6% |
| 2021 | 58.7% | -582.6% | -583.1% |
Download Data
Export DNA earnings history in CSV or JSON format
Free sign-in required to download data
Ginkgo Bioworks Holdings, Inc. (DNA) Earnings Overview
As of May 8, 2026, Ginkgo Bioworks Holdings, Inc. (DNA) reported trailing twelve-month net income of -$304M, reflecting +46.5% year-over-year growth. The company earned $-5.11 per diluted share over the past four quarters, with a net profit margin of -183.8%.
Looking at the long-term picture, DNA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$119M in fiscal 2019.
Ginkgo Bioworks Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including BEAM (-$65M net income, -57.2% margin), TWST (-$81M net income, -20.6% margin), SRPT ($65M net income, -32.5% margin), DNA has room to improve margins relative to the peer group. Compare DNA vs BEAM →
DNA Earnings vs Peers
Earnings metrics vs comparable public companies
DNA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$313M | +42.8% | -$315M | $-5.64 | -183.8% | -185.3% |
| 2024 | -$547M | +38.7% | -$560M | $-10.54 | -240.9% | -246.5% |
| 2023 | -$893M | +57.6% | -$864M | $-18.40 | -355.1% | -343.8% |
| 2022 | -$2.10B | -15.0% | -$2.21B | $-50.20 | -440.6% | -462.4% |
| 2021 | -$1.83B | -1345.4% | -$1.83B | $-55.53 | -583.1% | -582.6% |
| 2020 | -$127M | -6.1% | -$137M | $-4.00 | -165.2% | -178.8% |
| 2019 | -$119M | - | -$72M | $-4.15 | -220.2% | -132.1% |
See DNA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DNA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DNA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDNA — Frequently Asked Questions
Quick answers to the most common questions about buying DNA stock.
Is DNA growing earnings?
DNA EPS is $-5.11, with earnings growth accelerating to +46.5%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-304M.
What are DNA's profit margins?
Ginkgo Bioworks Holdings, Inc. net margin is -183.8%, with operating margin at -185.3%. Below-average margins reflect competitive or cost pressures.
How consistent are DNA's earnings?
DNA earnings data spans 2019-2025. The accelerating earnings trend is +46.5% YoY. Historical data enables comparison across business cycles.